Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes...

Details Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes... Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes...

2006-10-10

2006-10-10

Coleman, Brenda (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C514S274000

Reexamination Certificate

active

07119202

ABSTRACT:
Disclosed are compounds of the formulawherein R1is hydrogen or an acyl group having 1 to 16 carbon atoms;R2is a purine or pyrimidine base or an analogue or derivative thereof;Z is O, S, S═O or SO2; andpharmaceutically acceptable derivatives thereof.Also described are processes for and intermediates of use in their preparation, pharmaceutical compositions containing these compounds, and the use of these compounds in the antiviral treatment of mammals.

REFERENCES:
patent: 4000137 (1976-12-01), Dronch
patent: 4336381 (1982-06-01), Nagata
patent: 4415573 (1983-11-01), Ochi
patent: 5039667 (1991-08-01), Tyrrell
patent: 5118672 (1992-06-01), Schinazi
patent: 5204466 (1993-04-01), Liotta
patent: 5210085 (1993-05-01), Liotta
patent: 5539116 (1996-07-01), Liotta et al.
patent: A-0 206 497 (1986-12-01), None
patent: B-0 212 409 (1987-03-01), None
patent: A-0 337 713 (1989-01-01), None
patent: A-0 349 242 (1990-01-01), None
patent: A-0 363 582 (1990-04-01), None
patent: A-0 382 526 (1990-08-01), None
patent: 2 063 257 (1981-06-01), None
patent: 2 230 266 (1990-10-01), None
patent: 0059171 (1977-05-01), None
patent: 0021178 (1978-02-01), None
patent: 0167685 (1981-12-01), None
patent: 0169689 (1981-12-01), None
patent: 1035023 (1983-08-01), None
patent: WO 88/08001 (1988-10-01), None
patent: WO 89/04662 (1989-06-01), None
patent: WO 90/12023 (1990-10-01), None
patent: WO 91/01326 (1991-02-01), None
patent: WO 91/11186 (1991-08-01), None
patent: WO 91/17159 (1991-11-01), None
Decision in Patent Interference No. 103,906, 2001.
Decision in Patent Interference No. 104,333, 2001.
Decision in Patent Interference No. 104,396, 2001.
Decision in Patent Interference No. 104,523, 2003.
Decision in Patent Interference No. 104,524, 2003.
M. Baba et al., “Both 2′,3′-Dideoxythymidine and Its 2′,3′-Unsaturated Derivative (2′,3′-Dideoxythymidinene) are Potent and Selective Inhibitors of Human Immunodeficiency Virus Replication in Vitro”,Biochem. Biophys. Res. Commun., 142, pp. 128-134 (1987).
J. Balzarini et al., “Potent and Selective Anti-HTLV-III/LAV Activity of 2′,3′-Dideoxycytidinene, the 2′,3′-Unsaturated Derivative of 2′,3′-Dideoxycytidine”,Biochem. Biophys. Res. Commun., 140, pp. 735-742 (1986).
B. Belleau et al., “Design and Activity of a Novel Class of Nucleoside Analogs Effective Against HIV-1”,V Intl. Conf. on AIDS Abs., T.C.O.1, p. 515 (1989).
R. Carlisle et al., “Cellular Pharmacology of the Anti-HIV BCH-189 (2′-Deoxy-3′-thiacytidine) in Human Peripheral Blood Mononuclear Cells (PBMC)”Am. Assoc. Cancer Res. Abs.(81st Annu. Mtg.), 2435, p. 410 (1990).
G. Gosselin et al., “Systematic Synthesis and Biological Evaluation of α- and β-D-Lyxofuranosyl Nucleosides of the Five Naturally Occurring Nucleic Acid Bases”,J. Med. Chem., 30, pp. 982-991 (1987).
E. Hallonquist & H. Hibbert, “Studies on Reactions Relating to Carbohydrates and Polysaccharides—XLIV. Synthesis of Isomeric Bicyclic Acetyl Ethers”,Canadian J. Res., 8, pp. 129-133 (1933).
P. Herdewijn et al., “3′-Substituted 2′,3′-Dideoxynucleoside Analogues as Potential Anti-HIV (HTLV-III/LAV) Agents”,J. Med. Chem., 30, pp. 1270-1278 (1987).
D. Huryn et al. “Synthesis of Iso-ddA, Member of a Novel Class of Anti-HIV Agents”,Tetrahedron Lett., 30, pp. 6259-6262 (1989).
D. Huryn et al. “Synthesis of Iso-ddA, Member of a Novel Class of Anti-HIV Agents: Dioxolane-T, A New 2′,3′-Dideoxynucleoside Prototype with In Vitro Activity against HIV”,Chemtracts—Org. Chem., 3, pp. 249-251 (B. Ganem ed., 1990).
T. Lin et al., “Synthesis and Antiviral Activity of Various 3′-Azido, 3′-Amino, 2′,3′-Unsaturated, and 2′,3′-Dideoxy Analogues of Pyrimidine Deoxyribonucleosides against Retroviruses”,J. Med. Chem., 30, pp. 440-444 (1987).
H. Mitsuya et al., “3′-Azido-3′-deoxythymidine (BW 4509U): An Antiviral Agent that Inhibits the Infectivity and Cytopathic Effect of Human T-Lymphotropic Virus Type III/Lymphadenopathy-Associated Virus In Vitro”,Proc. Natl. Acad. Sci. USA, 82, pp. 7096-7100 (1985).
H. Mitsuya & S. Broder, “Inhibition of the In Vitro Infectivity and Cytopathic Effect of Human T-Lymphotrophic Virus Type III/Lymphadenopathy-Associated Virus (HTLV-III/LAV) by 2′,3′-Dideoxynucleosides”,Proc. Natl. Acad. Sci. USA, 83, pp. 1911-1915 (1986).
D. Norbeck et al., (±)-Dioxolane-T ((±)-1-[(2β,4β)-2-(hydroxymethyl)-4-dioxolanyl]thymine),Tetrahedron Lett., 30, pp. 6263-6266 (1989).
M. Wainberg et al., “Anti-HIV-1 Activity, Toxicity and Pharmacokinetics of Totally Novel Nucleoside Analogs”,V Intl. Conf. on AIDS Abs., M.C.P.63, p. 552 (1989).
M. Wainberg et al., “Characterization of AZT-Resistant Isolates of HIV-1: Susceptibility to Deoxythiacytidine and Other Nucleosides”,6th Intl. Conf. on AIDS Abs., 3, S.B.87, p. 117 (1990).
Belleau's Reply Brief at Final Hearing in Interference No. 104,201, Aug. 1999.
Belleau Brief for Final Hearing in Interference No. 104,201, Aug. 1999.
Liotta's Reply to Belleau Brief for Final Hearing (corrected copy submitted Sep. 29, 1999) in Interference No. 104,201.
Brief for Final Hearing of the Junior Party Liotta et al. in Interference No. 104,201, Sep. 1999.
Nov. 7, 1998 letter from B. Zacharie at BioChem to H. Nishimura at Daicel Chemical Industries, Ltd. along with a return letter from H. Nishimura. (Document ID: BCH 003382-85).
Apr. 13, 1989 letter from B. Zacharie to H. Nishimura and a Jun. 8, 1989 return letter from H. Nishimura. (Document ID: BCH 003389-92).
Apr. 20, 1989 letter from N.L. Cooper of Glaxo to J. McDonald of BioChem. (Document ID: G 10070-72).
Meeting report for the July 20-21, 1989 meeting between BioChem and Glaxo. (Document ID: G 10131-61).
Sep. 1989 BioChem report on its nucleoside research and development program. (Document ID: BCH 029913-19).
Circa Oct. 1989 handwritten preliminary report from B. Zacharie of BioChem. (Document ID: BCH 135971-74).
Nov. 14, 1989 letter from J. Wilson of Supelco, Inc. (U.S.) to J. Daley of Supelco Ltd. (Canada). (Document ID: BCH 001720-22).
Development proposal for BCH-189 submitted by Glaxo personnel on Dec. 8, 1989. (Document ID: G 10289-304).
BioChem summary of its research program in nucleoside analogs dated Dec. 15, 1989. (Document ID: G 10305-14).
Redacted copy of Dec. 15, 1989 summary of BioChem's research program in nucleoside analogs. (Document ID: BCH 029825-31).
Glaxo progress report dated Apr. 2, 1990 reflecting work conducted from Apr. 1989-Mar. 1990. (Document ID: G 10478-539).
Glaxo progress report dated Apr. 4, 1990 on the biological properties of the enantiomers of BCH-189. (Document ID: G 10558-73).
Copy of Apr. 4, 1990 Glaxo report regarding the biological properties of the enantiomers of BCH-189. (Document ID: BCH 031353-68).
Three letters: Jun. 1, 1990 letter from T. Mansour of BioChem to R. Storer of Glaxo; Apr. 26, 1989 letter from G.Dionne of BioChem to N.L. Cooper of Glaxo; Apr. 20, 1989 letter from N.L. Cooper at Glaxo to J. McDonald of BioChem. (Document ID: BCH 031305-11).
Aug. 10, 1990 Glaxo report titled “Separation of the Enantiomers of IAF BioChem Nucleosides.” (Document ID: G 10965-75).
Copy of Aug. 10, 1990 Glaxo report regarding the separation of enantiomers of BCH-189. (Document ID: BCH 031342-52).
Oct. 9, 1990 Glaxo report on its enrichment of the enantiomers of BCH-189 using chiral acids accomplished during the Jun.-Jul. 1990 period. (Document ID: G 10948-50).

Affiliated with

Also associated with

Rating

Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3649289